AMSL signs exclusive distribution agreement with Valeritas Holdings, Inc.
Posted Apr 18, 2018.AMSL announces distribution agreement with Valeritas
Sydney, Australia, April 18, 2018 --- AMSL Diabetes are pleased to announce they have signed an exclusive distribution agreement with Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company which offers patients with type 2 diabetes products to help their day to day insulin management. Under the terms of the agreement, AMSL Diabetes will have the rights to promote, market and sell certain Valeritas products to diabetes clinics and patients in Australia.
“We are excited to offer our products to patients with type 2 diabetes in Australia, and thrilled to be partnered with AMSL Diabetes,” said John Timberlake, CEO and President of Valeritas. “Our decision to partner with AMSL Diabetes was driven by our goal of choosing the best distributor in Australia.”
“Our agreement with Valeritas is a significant step towards addressing the needs of Australian patients with type 2 diabetes who want simple and effective insulin management that doesn’t interfere with their way of life,” said Richard Plowright, Managing Director of AMSL. “We’re delighted with our exclusive partnership with Valeritas, and we’re looking forward to seeing the benefits it will bring to patients across Australia.”
Valeritas will retain responsibility for product development, regulatory approval, quality management, and manufacturing while AMSL Diabetes will be responsible for sales, marketing, customer support and distribution activities in Australia.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercialising innovative technologies.. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.